Enhertu approved in EU in post-ET breast cancer
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
L-HPC was independently developed by Shin-Etsu Chemical as a disintegrant for tablets
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Omega 3 oil 18 EPA/12 DHA is highly demanded worldwide for its multiple benefits for human and animal health
Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring
Nipaguard SCE Vita delivers comprehensive antimicrobial protection for personal care formulations
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Overall investment in the US facility is estimated around US$50 million
VITADEETM Green is a 100% plant-based Vitamin D3 suitable for food & nutraceuticals
Subscribe To Our Newsletter & Stay Updated